Menu
Search
|

Menu

Close
X

Fluidigm Corp FLDM.OQ (NASDAQ Stock Exchange Global Select Market)

6.01 USD
-0.32 (-5.06%)
As of 12:00 PM EDT
chart
Previous Close 6.33
Open 6.33
Volume 9,012
3m Avg Volume 54,741
Today’s High 6.33
Today’s Low 5.99
52 Week High 8.38
52 Week Low 2.52
Shares Outstanding (mil) 38.92
Market Capitalization (mil) 246.34
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
25
FY17
102
FY16
104
FY15
115
EPS (USD)
FY18
-0.341
FY17
-1.897
FY16
-2.620
FY15
-1.925
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.89
Price to Sales (TTM)
vs sector
2.42
8.00
Price to Book (MRQ)
vs sector
5.07
4.21
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
337.95
17.41
LT Debt to Equity (MRQ)
vs sector
337.95
13.26
Return on Investment (TTM)
vs sector
-22.76
13.14
Return on Equity (TTM)
vs sector
-129.96
15.15

EXECUTIVE LEADERSHIP

Samuel Colella
Independent Chairman of the Board, Since 2000
Salary: --
Bonus: --
Stephen Linthwaite
President, Chief Executive Officer, Chief Operating Officer, Director, Since 2016
Salary: --
Bonus: --
Vikram Jog
Chief Financial Officer, Principal Accounting Officer, Since 2018
Salary: $320,000.00
Bonus: $82,000.00
William Smith
Executive Vice President - Legal Affairs, General Counsel, Secretary, Since 2012
Salary: $325,000.00
Bonus: $83,000.00
Robert Jones
Executive Vice President - Research and Development, Since 2005
Salary: $320,000.00
Bonus: $82,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

7000 Shoreline Ct Ste 100
SOUTH SAN FRANCISCO   CA   94080-7603

Phone: +1650.2666000

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

SPONSORED STORIES